Inequalities in Compliance with the Two-Dose Measles Vaccination in Peruvian Children Aged 12 to 59 Months in 2023

Claudio Intimayta-Escalante (1), Gustavo Tapia-Sequeiros (2), Luis E. Cueva-Cañola (3)

1. Facultad de Medicina de San Fernando, Universidad Nacional Mayor de San Marcos, Lima, Peru.

2. Centro de Investigación de Estudiantes de Medicina, Universidad Privada de Tacna, Tacna, Peru.

3. Facultad de Medicina Humana, Universidad Nacional de Piura, Piura, Peru.

ABSTRACT

Introduction: Inadequate measles vaccination coverage leads to outbreaks that affect the pediatric population in Peru. The aim of this study was to evaluate sociodemographic inequalities related to the coverage and compliance in the two-dose measles vaccination schedule among Peruvian children in 2023. **Methods:** An analytical cross-sectional study was conducted using data from a national Peruvian survey. Mothers aged 15 to 49 with children aged 12 to 59 months were included. Sociodemographic and health characteristics of the mother and child were considered sources of inequality. Prevalence ratios (PR) were calculated to measure the characteristics associated with adherence to the measles vaccination schedule. Inequality analysis was assessed using the Erreygers Concentration Index (ECI). **Results:** A total of 8,148 households were evaluated. Vaccination coverage was identified as 85.9% (95%CI: 94.7 - 87.1) for the first dose and 53.9% (95%CI: 52.1 - 55.7) for the second dose. In the inequality analysis, mothers with no education (CI: -0.57), aged 15 to 17 years (CI: -0.38), residing in the jungle (CI: -0.41) or highlands (CI: -0.26), and without health insurance (CI: -0.01) showed greater inequality in adherence to the vaccination schedule. Additionally, adherence to growth and development check-ups in infants was a source of inequality (CI: -0.09). **Conclussion:** Measles vaccination coverage included education level, age, region of residence, area of residence, health insurance status, and adherence to growth and development check-ups.

Keywords: Measles; Measles Vaccine; Healthcare Disparities; Health Inequities; Socioeconomic Factors; Peru.

INTRODUCTION

Immunizations are one of the most effective measures for preventing diseases, as they prevent between 2 and 3 million deaths annually worldwide (1-3). Measles is highly contagious among the pediatric population and presents with symptoms such as diarrhea, ear infections, blindness, pneumonia, encephalitis, and, in some cases, can lead to death (4). In many countries, including the United States and the United Kingdom, the measles, mumps, and rubella (MMR) vaccine is distributed free of charge (5). The first dose is typically administered at 12 months of age, with a booster dose given at 6 years of age, following the recommended vaccination schedule.

In 2019, the World Health Organization (WHO) estimated 869,770 cases and 207,500 deaths due to measles (7). The global immunization rate declined by 5% from 2019 to 2021, possibly due to factors such as vaccine hesitancy, disruptions in healthcare services, or logistical challenges. This situation, exacerbated by the COVID-19 pandemic, primarily affected low-and middle-income countries (8). Only 7 out of 40 countries attained a minimum coverage of 95% to prevent measles outbreaks in 2024, highlighting the persistent risk of widespread outbreaks in regions with low vaccination rates.

In Peru, immunization coverage against measles was estimated at 70.2% and 52% for the first and second doses, respectively, in 2017 (11). However, due to reduced immunization coverage

during the pandemic, measles cases became more frequent (12, 13). Low vaccination rates can be attributed to public unawareness, such as misinformation spread on social media. In addition, inadequate healthcare supplies, like shortages of vaccines or insufficient training of healthcare personnel, can lead to errors in vaccine administration (14). However, there is no specific evidence regarding how sociodemographic conditions influence inequality in completing the immunization schedule. Therefore, the aim of this study was to evaluate sociodemographic inequalities associated with coverage and adherence to the two-dose measles vaccination schedule among Peruvian children aged 12 to 59 months in 2023.

METHODS

Study Design

We conducted an analytical cross-sectional study using data from the 2023 Demographic and Family Health Survey (or ENDES, in Spanish acronym) (15). The National Institute of Statistics and Informatics (or INEI, in Spanish acronym) conducts the ENDES survey every year since 2004 in urban and rural areas throughout Peru's regions, including the constitutional province of Callao. Mothers aged 15 to 49 years with Peruvian children aged 12 to 59 months who responded to questions about sociodemographic charancteristics and health issues like insurance affiliation, prenatal care visits, and immunization were also evaluated.

Variables Related to the Mothers

Sociodemographic and health characteristics were evaluated, such as age group (18 to 24, 25 to 34, 35 to 49 years), educational level (no education, primary, secondary, or higher), wealth index (first, second, third, fourth, and last quintile), area of residence (rural and urban), and natural region of residence (Lima, rest of the coast, highlands, and jungle). Additionally, health-related aspects, including insurance affiliation (yes or no) and receipt of tetanus vaccination during pregnancy, were examined. The assessment included identifying if the childbirth took place at a health center (yes or no).

Variables Related to the Child

Additionally, the evaluation included determining if children received the initial dose of measles vaccination and the booster or second dose of measles vaccination. A child was considered to have completed both doses if the vaccination was recorded on the card, with the date documented, or if the mother reported the immunization. The child's age in months was assessed in ranges (12 to 23 months, 24 to 35 months, 36 to 47 months, and 48 to 59 months), along with evaluating if they received growth and development check-ups (yes or no).

Statistical Analysis

The statistical analysis was conducted using STATA version 17.0, incorporating the complex sample design of the ENDES. Categorical variables were described using frequencies and percentages, along with their respective 95% confidence intervals weighted by the design effect. The study used the Rao-Scott chi-square test to analyze differences in the proportion of children who completed both doses of measles vaccination across different categories of the study variables. The analysis aimed to explore the connection between the assessed characteristics of mothers and children and the completion of both measles vaccination doses. We used Poisson regression models with strong variances to find the crude prevalence ratio (cPR) and the adjusted prevalence ratio (aPR), taking into account all the others characteristics.

Inequality Analysis

The inequality analysis was conducted using concentration curves to assess the compliance of the doses of measles vaccination based on socioeconomic status, ranging from the poorest to the richest. The concentration index (CI) was calculated by evaluating the area above or below the concentration curve. Poverty-related inequality is associated with situations that lean toward accumulation above the curve (16). Additionally, the Erreygers Concentration Index (ECI) was used to ensure a fairer calculation by considering the extremes of the evaluated health service distribution. Also, maps were generated to depict the inequality in immunization coverage among the regions of Peru.

Ethical Aspects

The study was conducted by analyzing data from ENDES, a national survey administered with informed consent from participants. Additionally, the study did not have information that would allow the identification of participants included in the research.

RESULTS

Among the 8,148 households included in the study, a coverage of 85.9% (95%CI: 84.7 – 87.1) for the first dose and 53.9% (95%CI: 52.1 – 55.7) for the booster dose of the measles vaccine was identified. Evaluating maternal characteristics revealed that sociodemographic factors (age group, educational level, wealth index, natural region, and area of residence) and health factors during pregnancy (prenatal care, receipt of tetanus vaccine, and institutional childbirth) mediated significant differences in the proportion of vaccinated infants (p<0.05). Similarly, infant age and participation in growth and development check-ups were found to determine significant differences in the proportion of vaccinated infants (p<0.05).

Additionally, it was identified that 52.1% (95%CI: 50.3 - 54.0) of infants completed both doses of vaccination. Evaluating maternal characteristics revealed that maternal age group, educational level, natural region, and area of residence, as well as receiving prenatal care, tetanus vaccination during pregnancy, and institutional childbirth, mediated significant differences in the proportion of infants vaccinated with the first dose (p < 0.05). Furthermore, infant age and participation in growth and development check-ups were found to mediate differences in vaccination proportion among these infants (p < 0.05). However, this was not the case for the proportion of infants vaccinated with the booster dose, among whom only certain maternal characteristics such as age group, area of residence, receiving prenatal care, tetanus vaccination during pregnancy, and institutional childbirth mediated significant differences (p<0.05). Similarly, this was observed for infant age in months within this group (Table 1).

In the analysis of inequality in the completion of the two doses of measles vaccination mediated by wealth quintile (Figure 1), it was identified that mothers without education (CI: -0.57), aged 15 to 17 years (CI: -0.38), residing in the jungle region (CI: -0.41) and highlands (CI: -0.26), as well as rural areas (CI: -0.73) and without health insurance (CI: -0.01) showed greater inequality (Table 2). Meanwhile, infants without growth and development monitoring exhibited higher inequality in completing the two doses of measles vaccination (CI: -0.09).

In assessing the prevalence of measles immunization, it was identified that children of women who had six or more prenatal care visits during pregnancy had a higher prevalence of 13.0% for vaccination with the first dose (aPR: 1.13, 95%CI: 1.07 –

1.19, p<0.001), as well as those children of mothers who had a higher prevalence of 7.8% for vaccination with the first dose during pregnancy (aPR: 1.08, 95%CI: 1.04 – 1.12, p<0.001). On the other hand, it was identified that children of mothers who had institutional childbirth had a higher prevalence of 10% (aPR: 1.10, 95%CI: 1.04 – 1.17, p=0.004) for measles immunization with the first dose. Similarly, it was found that the prevalence of immunization with the first dose increased as children got older, as well as among those who had growth and development check-ups (Table 3).

In evaluating the prevalence of measles booster immunization, it was identified that children of women who had six or more prenatal care visits during pregnancy had a higher prevalence of 18.4% for vaccination (aPR: 1.18, 95%CI: 1.06 - 1.33, p=0.004), compared to children of women with fewer than six prenatal care visits. On the other hand, it was found that children of women who had institutional childbirth and received tetanus vaccination during pregnancy had a higher prevalence of 9.9% and 7.7%, respectively, for vaccination with the booster dose. Additionally, it was observed that the prevalence of immunization with the booster dose increased with children's age, as well as among those who had growth and development check-ups (Table 3).

In assessing the prevalence of measles immunization with both doses, it was found that children of women who had six or more prenatal care visits during pregnancy had a higher prevalence of 19.7% for vaccination (PRa: 1.20, 95%CI: 1.07 - 1.35, p=0.002), compared to children of women with fewer than six prenatal care visits. On the other hand, it was identified that children of women who had institutional childbirth and received tetanus vaccination during pregnancy had a higher prevalence of 32.4% and 14.2%, respectively, for vaccination with both doses. Additionally, it was observed that the prevalence of immunization with both doses increased with children's age, as well as among those who had growth and development checkups (Table 3).

In the assessment of inequality in measles immunization with one and/or two doses using the Erreygers Concentration Index (ECI), it was found that vaccination was concentrated in the lower wealth quintiles among children of women residing in the jungle region, without education, and who received tetanus vaccination during pregnancy. This pattern was also observed for children with growth and development monitoring. Conversely, the inequality in vaccination with both doses concentrated in the lower wealth quintiles was lower among children of women without education, with secondary education, and health insurance. Similarly, this was the case for children without growth and development monitoring (Table 4).

In the assessment of measles immunization coverage across the 25 regions in Peru, it was identified that the departments of Apurímac, Ancash, Piura, and Tumbes had the highest immunization coverage. Conversely, the departments of Ucayali, Madre de Dios, Puno, and Amazonas had the lowest immunization coverage rates. Regarding inequality in immunization coverage with both doses of measles vaccine, it was found that the departments of Moquegua, Huancavelica, and Puno had higher inequality, whereas regions like Amazonas, Loreto, and Ucayali exhibited lower inequality (Figure 2).

DISCUSSION

This study examined inequalities in measles vaccination rates based on sociodemographic factors among Peruvian children aged 12 to 59 months. Our findings demonstrate inequality in both the first and second doses of vaccination, primarily mediated by sociodemographic factors such as maternal education level, age, and area of residence. Similarly, health-related factors such as the number of prenatal and growth and development check-ups for the child were associated with vaccination disparity.

Access to healthcare services in Peru is difficult, which worsens disparities in measles vaccination (18). In rural areas of the highlands and rainforests, the distance to vaccination centers forces the population to endure long journeys through strenuous walks or inadequate transportation means (19,20). This entails direct costs such as fares and consultation fees, as well as indirect costs like loss of income due to time spent traveling to vaccination sites (21). Therefore, this situation, coupled with poverty and low education levels, contributes to the abandonment of vaccination programs (22,23).

In contrast, urban areas enjoy privileged access to private healthcare services and have higher levels of health literacy (24,25). Moreover, due to the population density in these areas, they are the primary target of immunization campaigns (26,27). However, it is necessary to implement strategies such as verifying immunization in educational centers and disseminating information through social networks with clear messages in multiple languages to raise awareness among the population and improve vaccination coverage (28,29).

Mothers with higher formal education have children with less inequality in the coverage of both doses of measles vaccination. Mothers with higher education tend to better understand the importance of vaccination and have more resources available to vaccinate their children (30,31). Additionally, this group can more easily discern misinformation about vaccination risks in children (32). Therefore, education influences individual and collective decisions about vaccination, which can be improved through the implementation of educational strategies and policies that ensure equitable access to vaccines for the entire population (33).

Mothers with health insurance showed less inequality in completing measles vaccination doses. This is because the national

immunization strategy for children under six years ensures free vaccine administration at all health facilities (34). Therefore, insured mothers can ensure completing their children's vaccination schedule at different stages of their lives (35). However, some studies indicate that having health insurance may still lead to increased disparities in vaccination access, potentially because of differences in healthcare coverage and quality in countries like Peru (36-38).

Children enrolled in the Growth and Development Monitoring Program showed less inequality in completing the two doses of measles vaccination in Peru. This program offers child health assessments and emphasizes the importance of vaccination (39). Thus, even under unfavorable sociodemographic conditions, participation in this program can lead to higher immunization rates (40). However, conducting multiple activities during consultations and their limited duration may hinder discussions about the vaccination schedule (41). Strategies such as providing personalized information and sending reminders via phone calls or text messages have been shown to increase visits to health centers to complete the vaccination schedule (42,43).

In Peru, the average age of first pregnancy ranges from 21 to 23 years (44). Thus, a lack of experience and information among young pregnant women may reduce adherence to the immunization schedule (45,46). Additionally, young pregnant women are more exposed to biased information regarding the negative effects of vaccination on their children (47). An effective strategy has been training on infant health topics during prenatal check-ups (48). This setting is ideal due to the number of sessions and attentiveness provided by healthcare personnel (49), which enhances trust and satisfaction among pregnant women and increases their participation in postpartum vaccination programs (50).

Challenges such as insufficient supplies, healthcare system gaps, and poor monitoring limit childhood immunization (51,52). Therefore, prioritizing vaccination in areas with low coverage or outbreaks is crucial for preventing outbreaks (53). In low-and middle-income countries, knowledge of the vaccination schedule is often deficient due to a lack of records (54). Thus, informative sessions and a surveillance system can enhance immunization in healthcare centers (55). Therefore, assessing the effectiveness of these interventions in Peru is recommended to decrease the incidence of measles and other preventable diseases.

The study had some limitations because it was not possible to address mothers' perceptions for not vaccinating their children or the difficulties they faced when seeking to complete the immunization schedule. Also, the regional level scope of the DHS prevents us from assessing coverage at the provincial and district levels to address the areas at highest risk of measles outbreaks in Peru. In conclusion, inequalities in vaccination coverage with the first dose and booster dose against measles were greater among children aged 12 to 59 months of women living in rural areas or outside Lima Metropolitan area, lower education, and without health insurance. Additionally, vaccination rates were primarily concentrated among children whose mothers during pregnancy had six or more prenatal check-ups, received tetanus vaccines, and had institutional deliveries.

Corresponsal Author:

Claudio Intimayta-Escalante

E-mail: claudio.intimayta@unmsm.edu.pe

© ORCID: https://orcid.org/0000-0003-2552-9974

Conflict of interests: None.

Funding: Self-funded

Acknowledgements: None.

REFERENCES

 United Nations. Vaccines prevent between 2 and 3 million deaths annually, according to the WHO. New York: UN;2016. Available from: https://news.un.org/es/story/2016/04/1355531
 Cáceres Bermejo GG. A Moment of Reflection on Vaccines. Sanid. Mil. 2012;68(2):109-14. doi: 10.4321/S1887-85712012000200009

3. Pan American Health Organization, World Health Organization. Immunization. Washington DC: PAHO/WHO; 2024. Available from: https://www.paho.org/es/temas/inmunizacion

4. Pan American Health Organization, World Health Organization. Measles. Washington DC: PAHO/WHO;2024. Available from: https://www.paho.org/es/temas/sarampion

5. Costa-Alcalde JJ, Trastoy-Pena R, Barbeito-Castiñeiras G, Navarro de la Cruz D, Mejuto B, Aguilera A. Seroprevalence of Antibodies Against Measles Virus in Galicia: Trends Over the Last Ten Years by Age and Sex. Rev Esp Quimioter. 2020;33(2):116-21. doi: 10.37201/req/108.2019

6. Schwarz Chavarri G, Sánchez Hernández C, Moreno Millán N, Morató Agustí ML, Martín Martín S, Javierre Miranda AP, et al. Prevention of Infectious Diseases: Vaccine Update, 2020. Aten Primaria. 2020;52(Suppl 2):70-92. 10.1016/j.aprim.2020.08.001

7. World Health Organization. Global measles mortality increased by 50% from 2016 to 2019, claiming more than 207,500 lives in 2019. Ginebra: WHO; 2020. Available from: https://bit.ly/3X2mftr

8. Local Burden of Disease Vaccine Coverage Collaborators. Mapping routine measles vaccination in low- and middle-income countries. Nature. 2021;589:415–19. doi: 10.1038/s41586-020-03043-4

9. Pan American Health Organization, World Health Organization. Epidemiological Alert: Measles in the Region of the

Americas. Washington, DC: PAHO/WHO;2024. Available from: https://bit.ly/3yIoPKR

10. Minta AA, Ferrari M, Antoni S, et al. Progress Toward Measles Elimination — Worldwide, 2000–2022. MMWR Morb Mortal Wkly Rep 2023;72:1262–68. doi: 10.15585/mmwr.mm7246a3

11. Vásquez-Uriarte K, Ninatanta Ortiz JA, Romani F, Roque-Henriquez JC. Coverage and factors associated with measles vaccination in children aged 12-59 months in Peru: estimate based on the 2017 demographic and family health survey. Rev. peru. med. exp. salud publica. 2019;36(4):610-19. doi: 10.17843/rpmesp.2019.360.4456

12. Loayza-Alarico MJ, De La Cruz-Vargas JA. Measles: reemerging threat of epidemic in peru. Rev. Fac. Med. Hum. 2019;19(3):7-8. doi: 10.25176/RFMH.v19i3.2176

13. Pacheco FC, França GVA, Elidio GA, Leal MB, de Oliveira C, Guilhem DB. Measles-containing vaccines in Brazil: Coverage, homogeneity of coverage and associations with contextual factors at municipal level. Vaccine. 2020;38(8):1881-7. doi: 10.1016/j.vaccine.2020.01.030

14. Ropero Alvarez AM, Vilajeliu A, Magariños M, Jauregui B, Guzmán L, Whittembury A, et al. Enablers and barriers of maternal and neonatal immunization programs in Latin America. Vaccine. 2021;39:B34-43. doi: 10.1016/j.vaccine.2020.07.051
15. National Institute of Statistics and Informatics. Demographic and Family Health Survey - ENDES 2022. Lima: INEI; 2023. Available from: https://bit.ly/3VoBX0x

16. Wagstaff A, Paci P, van Doorslaer E. On the measurement of inequalities in health. Soc Sci Med. 1991;33(5):545-57. doi: 10.1016/0277-9536(91)90212-u

17. Erreygers G. Correcting the concentration index. J Health Econ. 2009;28(2):504-15. doi: 10.1016/j.jhealeco.2008.02.003

18. National Institute of Statistics and Informatics. Characteristics of the population accessing and not accessing health services in Peru. Lima: INEI; 2023. Available from: https://bit.ly/3V9ZVLI

19. Lazo-Porras M, Penniecook T. Health equity: access to quality services and caring for underserved populations. Health Policy Plan. 2023;38(Supplement-2):221-2. doi: 10.1093/heapol/czad073

20. Chung-Delgado K, Valdivia Venero JE, Vu TM. Vaccine Hesitancy: Characteristics of the Refusal of Childhood Vaccination in a Peruvian Population. Cureus. 2021;13(3):e14105. doi: 10.7759/cureus.14105

21. Hernández-Vásquez A, Vargas-Fernández R, Rojas-Roque C. Geographic and Socioeconomic Determinants of Full Coverage COVID-19 Vaccination in Peru: Findings from a National Population-Based Study. Vaccines (Basel). 2023;11(7):1195. doi: 10.3390/vaccines11071195

22. Ali HA, Hartner AM, Echeverria-Londono S, Roth J, Li X, Abbas K, et al. Vaccine equity in low and middle income countries: a systematic review and meta-analysis. Int J Equity Health. 2022;21(1):82. doi: 10.1186/s12939-022-01678-5

23. Castro A, Sáenz R, Avellaneda X, Cáceres C, Galvão L,

Mas P, et al. The Health Equity Network of the Americas: inclusion, commitment, and action. Rev Panam Salud Publica. 2021;45:e79. doi: 10.26633/RPSP.2021.79

24. Carrasco-Escobar G, Manrique E, Tello-Lizarraga K, Miranda JJ. Travel Time to Health Facilities as a Marker of Geographical Accessibility Across Heterogeneous Land Coverage in Peru. Front Public Health. 2020;8:498. doi: 10.3389/fpubh.2020.00498

25. Aljassim N, Ostini R. Health literacy in rural and urban populations: A systematic review. Patient Educ Couns. 2020;103(10):2142-2154. doi: 10.1016/j.pec.2020.06.007

26. Joe P, Majgi SM, Vadiraja N, Khan MA. Influence of Sociodemographic Factors in Measles-Rubella Campaign Compared with Routine Immunization at Mysore City. Indian J Community Med. 2019;44(3):209-212. doi: 10.4103/ijcm.IJCM-236-18

27. Pan American Health Organization. Urban health. Washington DC: PAHO;2024. Available from: https://www.paho.org/es/temas/salud-urbana

28. Stanescu A, Ruta SM, Cernescu C, Pistol A. Suboptimal MMR Vaccination Coverages-A Constant Challenge for Measles Elimination in Romania. Vaccines (Basel). 2024;12(1):107. doi: 10.3390/vaccines12010107

29. Ganczak M, Kalinowski P, Pasek O, Duda-Duma L, Sobieraj E, Go lawski J, et al. Health System Barriers to Child Mandatory and Optional Vaccination among Ukrainian Migrants in Poland in the Context of MMR and HPV Vaccines-A Qualitative Study. Int J Environ Res Public Health. 2022;20(1):712. doi: 10.3390/ijerph20010712

30. Griffith BC, Ulrich AK, Becker AB, Nederhoff D, Koch B, Awan FA, et al. Does education about local vaccination rates and the importance of herd immunity change US parents' concern about measles? Vaccine. 2020;38(50):8040-8048. doi: 10.1016/j.vaccine.2020.09.076

31. Gowda C, Schaffer SE, Kopec K, Markel A, Dempsey AF. A pilot study on the effects of individually tailored education for MMR vaccine-hesitant parents on MMR vaccination intention. Hum Vaccin Immunother. 2013;9(2):437-45. doi: 10.4161/hv.22821

32. Bethke N, O'Sullivan JL, Keller J, von Bernuth H, Gellert P, Seybold J. Increasing vaccinations through an on-site schoolbased education and vaccination program: A city-wide cluster randomized controlled trial. Appl Psychol Health Well Being. 2024. doi: 10.1111/aphw.12528

33. Haeder SF. U.S. public support and opposition to vaccination mandates in K-12 education in light of the COVID-19 pandemic. Vaccine. 2023;41(48):7103-7115. doi: 10.1016/j.vaccine.2023.10.016

34. Ministry of Health of Peru. Immunization is completely free in health facilities in all regions. Lima: MINSA; 2012. Available from: https://bit.ly/3X51woE

35. D'Ardenne KK, Darrow J, Furniss A, Chavez C, Hernandez H, Berman S, et al. Use of rapid needs assessment as a tool to identify vaccination delays in Guatemala and Peru. Vaccine. 2016;34(14):1719-25. doi: 10.1016/j.vaccine.2016.01.060

36. Cotter JC. Napa Immunization Study: Immunization Rates for Children with Publicly Funded Insurance Compared with those with Private Health Insurance in a Suburban Medical Office. Perm J. 201;15(4):12-22. doi: 10.7812/TPP/11-122

37. Blewett LA, Davidson G, Bramlett MD, Rodin H, Messonnier ML. The impact of gaps in health insurance coverage on immunization status for young children. Health Serv Res. 2008;43(5):1619-36. doi: 10.1111/j.1475-6773.2008.00864.x
38. González-Block MÁ, Arroyo-Laguna J, Rodríguez-Zea B, Pelcastre-Villafuerte BE, Gutiérrez-Calderón E, Díaz-Portillo SP, et al. The importance of confidence, complacency, and convenience for influenza vaccination among key risk groups in large urban areas of Peru. Hum Vaccin Immunother. 2021;17(2):465-474. doi: 10.1080/21645515.2020.1777821

39. Ministry of Health of Peru. Growth and Development Monitoring for children under 11 years old. Lima: MINSA; 2024. Available from: https://www.gob.pe/32588

40. Gonzales-Achuy E, Huamán-Espino L, Aparco JP, Pillaca J, Gutiérrez C. Factors associated with fulfillment of growth and development monitoring for children ;1 year of age in health centers in Amazonas, Loreto and Pasco. Rev Peru Med Exp Salud Publica. 2016;33(2):224-32. doi: 10.17843/rpmesp.2016.332.2187

41. Ramlawi S, Muldoon KA, Dunn SI, et al. Worries, beliefs and factors influencing perinatal COVID-19 vaccination: a cross-sectional survey of preconception, pregnant and lactating individuals. BMC Public Health. 2022;22:2418. doi: 10.1186/s12889-022-14617-4

42. Sato R, Titus T. Effect of tailored information of vaccination schedule on vaccine uptake in northern Nigeria. Hum Vaccin Immunother. 2021;17(10):3818-3822. doi: 10.1080/21645515.2021.1936861

43. Jacobson Vann JC, Jacobson RM, Coyne-Beasley T, Asafu-Adjei JK, Szilagyi PG. Patient reminder and recall interventions to improve immunization rates. Cochrane Database Syst Rev. 2018;1(1):CD003941. doi: 10.1002/14651858.CD003941.pub3

44. National Institute of Statistics and Informatics. In Peru, more than eight million 777 thousand women are mothers. Lima: INEI; 2022. Available from: https://bit.ly/4aQI6am

45. Atuyambe L, Mirembe F, Tumwesigye NM, Annika J, Kirumira EK, Faxelid E. Adolescent and adult first time mothers' health seeking practices during pregnancy and early motherhood in Wakiso district, central Uganda. Reprod Health. 2008;5:13. doi: 10.1186/1742-4755-5-13

46. Weiner JL, Fisher AM, Nowak GJ, Basket MM, Gellin

BG. Childhood Immunizations: First-Time Expectant Mothers' Knowledge, Beliefs, Intentions, and Behaviors. Am J Prev Med. 2015;49(6 Suppl 4):S426-34. doi: 10.1016/j.amepre.2015.07

47. Bradshaw AS, Shelton SS, Wollney E, Treise D, Auguste K. Pro-Vaxxers Get Out: Anti-Vaccination Advocates Influence Undecided First-Time, Pregnant, and New Mothers on Facebook. Health Commun. 2021;36(6):693-702. doi: 10.1080/10410236.2020.1712037

48. Hu Y, Chen Y, Wang Y, Song Q, Li Q. Prenatal vaccination education intervention improves both the mothers' knowledge and children's vaccination coverage: Evidence from randomized controlled trial from eastern China. Hum Vaccin Immunother. 2017;13(6):1-8. doi: 10.1080/21645515.2017.1285476

49. World Health Organization. The WHO states that pregnant women should have access to appropriate care at the right time. Ginebra: WHO;2016. Available from: https://bit.ly/3KnNFT0 **50.** Ley K, Hoq M, Leask J, Perrett KP, O'Keefe J, Giles ML, et al. Vaccine decision-making begins in pregnancy: Correlation between vaccine concerns, intentions and maternal vaccination with subsequent childhood vaccine uptake. Vaccine. 2018;36(44):6473-6479. doi: 10.1016/j.vaccine.2017.08.003

51. Hardt K, Bonanni P, King S, Santos JI, El-Hodhod M, Zimet GD, Preiss S. Vaccine strategies: Optimising outcomes. Vaccine. 2016;34(52):6691-6699. doi: 10.1016/j.vaccine.2016.10.078

52. Aslam F, Babar ZU, Madni A, Asghar M, Yue Y. Unveiling and addressing implementation barriers of vaccination communication strategy: Perspectives from government officials at national and provincial levels. Hum Vaccin Immunother. 2022;18(7):2153513. doi: 10.1080/21645515.2022.2153513

53. Bonanni P, Sacco C, Donato R, Capei R. Lifelong vaccination as a key disease-prevention strategy. Clin Microbiol Infect. 2014 May;20 Suppl 5:32-6. doi: 10.1111/1469-0691.12537

54. Mokdad AH, Gagnier MC, Colson KE, Dansereau E, Zúñiga-Brenes P, Ríos-Zertuche D, et al. Missed Opportunities for Measles, Mumps, and Rubella (MMR) Immunization in Mesoamerica: Potential Impact on Coverage and Days at Risk. PLoS One. 2015;10(10):e0139680. doi: 10.1371/journal.pone.0139680

55. Reifferscheid L, Kiely MS, Lin MSN, Libon J, Kennedy M, MacDonald SE. Effectiveness of hospital-based strategies for improving childhood immunization coverage: A systematic review. Vaccine. 2023;41(36):5233-5244. doi: 10.1016/j.vaccine.2023.07.036

medRxiv preprint doi: https://doi.org/10.1101/2024.06.03.24308410; this version posted June 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. TABLES Y FIGURES

Table 1. Characteristics of mothers and children according to coverage of the first and second doses of measles vaccine

Variables	First I	Ooses (n=6802)	Second Doses (n=4095)			
	Proportion according to characteristics %* (95%CI)	First dose coverage* (12 to 59 months) %* (95%CI)	P- value**	Proportion according to characteristics %* (95%CI)	Second dose coverage* (12 to 59 months) %* (95%CI)	P- value**
Mother's Characteristics	/0 ()5/001)	/0 ()3/001)		/0 ()3/0(1)	/0 ()3/001)	
Age Group						
15 to 17 years old	0.63 (0.4 a 0.9)	67.2 (46.2 a 83.0)	< 0.001	0.4 (0.2 a 0.9)	27 (13.0 a 47.8)	< 0.001
18 to 29 years old	37.2 (35.4 a 39.0)	82.3 (80.2 a 84.3)	01001	36.4 (34.2 a 38.6)	50.5 (47.7 a 53.2)	0.001
30 to 49 years old	62.2 (60.4 a 64.0)	88.5 (87.1 a 89.7)		63.2 (61.0 a 65.4)	56.4 (54.2 a 58.6)	
Educational Level	0212 (0011 4 0 110)	(o, u o,)		(0110 # 0011)	e of f (e fil <u>e</u> a e of o)	
No Education	0.8 (0.6 a 1.1)	79 (65.7 a 88.0)	< 0.001	0.9 (0.6 a 1.3)	54.9 (41.1 a 67.9)	0.605
Elementary	11.4 (10.4 a 12.5)	82.2 (78.9 a 85.0)	0.001	11.9 (10.6 a 13.3)	53.5 (49.5 a 57.5)	0.002
High School	45.6 (43.7 a 47.6)	84.4 (82.5 a 86.0)		45.7 (43.3 a 48.2)	52.9 (50.4 a 55.4)	
University	42.2 (40.3 a 44.2)	88.9 (87.0 a 90.6)		41.5 (39.1 a 44.0)	55.1 (52.1 a 58.1)	
Wealth Index	12.2 (10.5 a 11.2)	00.9 (07.0 u 90.0)		11.5 (59.1 u 11.0)	55.1 (52.1 u 50.1)	
Q5 (Last Quintile)	18.5 (17.5 a 19.7)	81.2 (78.8 a 83.3)	0.001	18.5 (17.1 a 19.9)	50.5 (47.7 a 53.3)	0.32
Q4 Q4	23.1 (21.7 a 24.6)	85.1 (82.8 a 87.2)	0.001	23.2 (21.5 a 25.1)	53.6 (50.5 a 56.6)	0.52
Q3	20.1 (18.6 a 21.7)	86.4 (83.5 a 88.9)		20.1 (18.2 a 22.2)	54.2 (50.6 a 57.8)	
Q2	20.3 (18.7 a 22.0)	87.7 (84.5 a 90.3)		20.4 (18.4 a 22.5)	55.6 (51.3 a 59.7)	
Q1 (First Quintile)	18.0 (16.3 a 19.8)	89.7 (86.1 a 92.5)		17.8 (15.9 a 19.9)	55.9 (50.4 a 61.3)	
Natural Region	10.0 (10.5 a 17.0)	0 <i>)</i> .7 (00.1 a <i>)</i> 2.3)		17.0 (15.7 d 17.7)	55.7 (50.4 d 01.5)	
Metropolitan Lima	36.0 (34.3 a 37.8)	87.7 (85.0 a 90.1)	0.008	35.4 (33.0 a 37.9)	54.3 (50.1 a 58.4)	0.216
Rest of the Coast	26.1 (24.8 a 27.5)	86.8 (84.6 a 88.7)	0.008	27 (25.2 a 28.9)	56.2 (53.4 a 59.0)	0.210
Highlands	23.8 (22.5 a 25.2)	84.9 (83.0 a 86.6)		23.6 (21.9 a 25.4)	52.6 (50.1 a 55.1)	
Jungle	14.0 (13.1 a 15.0)	81.8 (79.5 a 83.8)		14 (12.7 a 15.3)	51 (48.1 a 54.0)	
Area of Residence	14.0 (15.1 a 15.0)	01.0 (79.5 a 05.0)		14 (12.7 a 15.5)	51 (40.1 a 54.0)	
Urban	83.5 (82.52 a 84.40)	86.7 (85.3 a 88.0)	< 0.001	83.9 (82.6 a 85.1)	54.7 (52.6 a 56.8)	0.01
Rural	16.5 (15.60 a 17.48)	80.7 (85.5 a 88.0) 82.3 (80.0 a 84.3)	<0.001	16.1 (14.9 a 17.4)	50.1 (47.3 a 52.9)	0.01
Health Insurance	10.3 (13.00 a 17.46)	82.3 (80.0 a 84.3)		10.1 (14.9 a 17.4)	50.1 (47.5 a 52.9)	
Yes	93.4 (92.3 a 94.3)	86.2 (85.0 a 87.4)	0.037	93.6 (92.2 a 94.8)	54.3 (52.4 a 56.1)	0.137
No	6.6 (5.7 a 7.7)	80.2 (85.0 a 87.4) 81.7 (76.6 a 85.8)	0.037	6.4 (5.2 a 7.8)	48.9 (42.0 a 55.8)	0.137
Antenatal Care Visits	0.0 (<i>J. i a i</i> . <i>i</i>)	81.7 (70.0 a 85.8)		0.4 (J.2 a 7.8)	40.9 (42.0 a 55.6)	
Less than Six	12.1 (10.8 a 13.5)	77 (72.5 a 80.9)	< 0.001	11.4 (9.9 a 13.0)	45.9 (40.9 a 51.0)	< 0.001
Six or More	87.9 (86.6 a 89.2)	89.1 (87.9 a 90.3)	<0.001	88.6 (87.0 a 90.1)	45.9 (40.9 a 51.0) 56.7 (54.8 a 58.7)	<0.001
Received Tetanus Vaccine	07.9 (00.0 a 09.2)	09.1 (07.9 à 90.3)		00.0 (07.0 a 90.1)	50.7 (54.8 a 56.7)	
No	10.9(18.2 - 21.5)	80.9 (77.6 a 83.8)	< 0.001	18.3 (16.4 a 20.3)	$47.1(42.2 \times 50.0)$	< 0.001
Yes	19.8 (18.3 a 21.5) 80.2 (78.5 a 81.7)	80.9 (77.0 a 85.8) 89.1 (87.8 a 90.3)	<0.001		47.1 (43.3 a 50.9) 57.4 (55.4 a 59.5)	<0.001
	00.2 (70.3 à 01.7)	09.1 (07.0 à 90.3)		o1./(/9./ a o5.0)	57.4 (55.4 a 59.5)	
Institutional Labor	28(22 - 16)	70.2(62.2 - 76.5)	<0.001	22(26 - 20)	266(205 - 422)	<0.001
No	3.8 (3.2 a 4.6)	70.3 (63.2 a 76.5)	< 0.001	3.2 (2.6 a 3.9)	36.6 (30.5 a 43.3)	< 0.001
Yes Children's Characteristics	96.2 (95.4 a 96.8)	86.7 (85.5 a 87.8)		96.8 (96.1 a 97.4)	54.7 (52.9 a 56.5)	
Age (months)	20.4(10.0.21.0)	70.7(75.7.01.4)	<0.001	122(100, 120)	20.0(2(8.222))	<0.001
12 to 23	20.4 (19.0 a 21.8)	78.7 (75.7 a 81.4)	< 0.001	12.3 (10.9 a 13.8)	29.9 (26.8 a 33.2)	< 0.001
24 to 35	23.1 (21.6 a 24.7)	86.8 (84.3 a 89.0)		26.6 (24.7 a 28.7)	62.7 (59.1 a 66.1)	
36 to 47	27.9 (26.2 a 29.6)	88.8 (86.7 a 90.6)		30.3 (28.1 a 32.6)	60.6 (57.4 a 63.7)	
48 to 59	28.6 (27.0 a 30.3)	88.2 (86.2 a 89.9)		30.8 (28.6 a 33.0)	59.2 (56.0 a 62.4)	
Growth and Development						
Control		02.2 (01.1 07.1)	-0.001		52.1 (50.2 56.0)	0 450
No	39.2 (37.3 a 41.1)	83.3 (81.1 a 85.4)	< 0.001	39.8 (37.4 a 42.3)	53.1 (50.2 a 56.0)	0.456
Yes	60.8 (58.9 a 62.7)	87.6 (86.2 a 88.9)		60.2 (57.7 a 62.6)	54.4 (52.3 a 56.6)	

*Weighted estimate for the complex survey sample.

**p-value calculated using the Rao-Scott test.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.03.24308410; this version posted June 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. Table 2. Characteristics of mothers and children and inequality in compliance with the two doses of

measles vaccination

Variables	Complete Vacci Doses (n=39		Inequality in compliance with the two doses of measles vaccination against measles		
	%* (95%CI)	P-value	CI (95%CI)	P-value	
Mother's Characteristics					
Age Group					
15 to 17 years old	27 (13.0 a 47.8)	< 0.001	-0.376 (-0.665 a -0.086)	0.011	
18 to 29 years old	47.5 (44.7 a 50.4)		-0.116 (-0.16 a -0.071)	< 0.001	
30 to 49 years old	55.5 (53.2 a 57.7)		0.067 (0.043 a 0.091)	< 0.001	
Educational Level					
No Education	54.6 (40.8 a 67.7)	0.380	-0.573 (-0.763 a -0.383)	< 0.001	
Elementary	52.1 (48.1 a 56.2)		-0.515 (-0.576 a -0.455)	< 0.001	
High School	50.8 (48.2 a 53.4)		-0.163 (-0.198 a -0.128)	< 0.001	
University	53.7 (50.6 a 56.7)		0.331 (0.3 a 0.361)	< 0.001	
Natural Region					
Metropolitan Lima	53.3 (49.0 a 57.5)	0.257	0.299 (0.26 a 0.339)	< 0.001	
Rest of the Coast	53.5 (50.7 a 56.3)		-0.023 (-0.081 a 0.036)	0.449	
Highlands	51.1 (48.6 a 53.7)		-0.261 (-0.319 a -0.204)	< 0.001	
Jungle	48.7 (45.7 a 51.8)		-0.414 (-0.469 a -0.359)	< 0.001	
Area of Residence					
Urban	53.1 (50.9 a 55.2)	0.004	0.118 (0.101 a 0.134)	< 0.001	
Rural	47.8 (45.0 a 50.6)		-0.725 (-0.774 a -0.676)	< 0.001	
Health Insurance					
Yes	52.4 (50.5 a 54.3)	0.300	0.198 (0.091 a 0.305)	< 0.001	
No	48.6 (41.8 a 55.6)		-0.014 (-0.023 a -0.005)	0.002	
Antenatal Care Visits					
Less than Six	44.3 (39.3 a 49.3)	< 0.001	-0.078 (-0.163 a 0.007)	0.073	
Six or More	55.7 (53.7 a 57.6)		0.01 (-0.001 a 0.02)	0.063	
Received Tetanus Vaccine					
No	46.1 (42.2 a 49.9)	< 0.001	-0.003 (-0.006 a 0.001)	0.152	
Yes	56.2 (54.1 a 58.3)		-0.003 (-0.006 a 0.001)	0.152	
Institutional Labor					
No	34.3 (28.4 a 40.7)	< 0.001	0.022 (0.016 a 0.027)	< 0.001	
Yes	53 (51.2 a 54.9)		0.022 (0.016 a 0.027)	< 0.001	
Children's Characteristics					
Age (months)					
12 to 23	29.1 (26.0 a 32.4)	< 0.001	-0.061 (-0.133 a 0.011)	0.098	
24 to 35	59.8 (56.2 a 63.4)		-0.033 (-0.087 a 0.02)	0.226	
36 to 47	58.7 (55.3 a 62.0)		0.012 (-0.034 a 0.059)	0.600	
48 to 59	57.7 (54.4 a 60.9)		0.042 (-0.005 a 0.088)	0.079	
Growth and Development					
Control					
No	52.1 (49.1 a 55.0)	0.823	-0.094 (-0.124 a -0.064)	< 0.001	
Yes	52.5 (50.3 a 54.7)		0.132 (0.091 a 0.173)	< 0.001	

CI: Concentration Index

*Weighted estimate for the complex survey sample.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.03.24308410; this version posted June 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. Table 3. Association between mothers' and children's characteristics and compliance with two doses of measles vaccination


	Received First Dose		Received Second Dose		Received Both Doses	
Variables	aPR (95%CI)	P- value	aPR (95%CI)	P- value	aPR (95%CI)	P- value
Mother's Characteristics						
Age Group						
15 to 17 years old	REF		REF		REF	
18 to 29 years old	0.954 (0.927 a 0.982)	0.002	0.939 (0.882 a 1.001)	0.053	0.918 (0.859 a 0.981)	0.012
30 to 49 years old	0.86 (0.683 a 1.084)	0.202	0.736 (0.397 a 1.367)	0.332	0.751 (0.404 a 1.394)	0.364
Educational Level						
No Education	REF		REF		REF	
Elementary	0.974 (0.944 a 1.004)	0.090	0.992 (0.914 a 1.076)	0.842	0.988 (0.907 a 1.077)	0.792
High School	0.971 (0.928 a 1.016)	0.204	1.051 (0.95 a 1.162)	0.337	1.059 (0.954 a 1.175)	0.281
University	0.935 (0.831 a 1.052)	0.265	1.083 (0.846 a 1.388)	0.526	1.101 (0.858 a 1.414)	0.449
Wealth Index						
Q5 (Last Quintile)	REF		REF		REF	
Q4	0.978 (0.932 a 1.026)	0.360	0.991 (0.875 a 1.122)	0.884	0.999 (0.881 a 1.134)	0.989
Q3	0.982 (0.937 a 1.029)	0.444	1.011 (0.891 a 1.147)	0.863	1.002 (0.881 a 1.14)	0.973
Q2	0.976 (0.931 a 1.023)	0.313	1.014 (0.893 a 1.15)	0.832	1.005 (0.884 a 1.143)	0.939
Q1 (First Quintile)	0.95 (0.899 a 1.004)	0.068	0.98 (0.849 a 1.132)	0.786	0.978 (0.845 a 1.132)	0.762
Natural Region	× / /				· · · · · ·	
Metropolitan Lima	REF		REF		REF	
Rest of the Coast	1.006 (0.969 a 1.044)	0.765	1.035 (0.948 a 1.13)	0.446	1.026 (0.936 a 1.125)	0.586
Highlands	0.988 (0.949 a 1.028)	0.541	0.95 (0.865 a 1.044)	0.290	0.968 (0.878 a 1.067)	0.514
Jungle	0.991 (0.951 a 1.033)	0.683	0.99 (0.897 a 1.093)	0.845	1.001 (0.903 a 1.109)	0.990
Area of Residence	(111)				(, , , , , , , , , , , , , , , , , , ,	
Urban	REF		REF		REF	
Rural	0.997 (0.96 a 1.035)	0.870	0.975 (0.899 a 1.059)	0.552	0.963 (0.886 a 1.046)	0.373
Health Insurance	(0150 @ 11000)	0.070	01370 (01033 @ 11003)	0.002	013 02 (01000 4 110 10)	01070
Yes	REF		REF		REF	
No	1.043 (0.992 a 1.097)	0.097	1.099 (0.958 a 1.261)	0.180	1.076 (0.937 a 1.236)	0.300
Antenatal Care Visits	1.0 13 (0.992 a 1.097)	0.097	1.099 (0.900 u 1.201)	0.100	1.070 (0.957 @ 1.250)	0.200
Less than Six	REF		REF		REF	
Six or More	1.13 (1.071 a 1.193)	< 0.001	1.184 (1.056 a 1.327)	0.004	1.197 (1.066 a 1.345)	0.002
Received Tetanus Vaccine	1.15 (1.071 a 1.175)	-0.001	1.101 (1.050 u 1.527)	0.001	1.1 <i>9</i> / (1.000 u 1.5 15)	0.002
No	REF		REF		REF	
Yes	1.078 (1.036 a 1.121)	< 0.001	1.139 (1.046 a 1.241)	0.003	1.142 (1.045 a 1.247)	0.003
Institutional Labor	1.070 (1.050 a 1.121)	<0.001	1.137 (1.040 a 1.241)	0.005	1.142 (1.045 a 1.247)	0.005
No	REF		REF		REF	
Yes	1.1 (1.031 a 1.173)	0.004	1.319 (1.068 a 1.629)	0.010	1.324 (1.07 a 1.639)	0.010
Children's Characteristics	1.1 (1.051 a 1.175)	0.004	1.519 (1.008 a 1.029)	0.010	1.524 (1.07 a 1.059)	0.010
Age (months)	DFF		DEE		DFF	
12 to 23	REF	<0.001	REF	<0.001	REF	<0.001
24 to 35	1.15 (1.099 a 1.203)	< 0.001	2.461 (2.155 a 2.811) 2.422 (2.122 a 2.766)	<0.001	2.44 (2.133 a 2.792) 2.41 (2.107 a 2.757)	< 0.001
36 to 47	1.174 (1.124 a 1.225)	< 0.001	2.423 (2.122 a 2.766)	< 0.001	2.41 (2.107 a 2.757)	< 0.001
48 to 59	1.153 (1.101 a 1.207)	< 0.001	2.352 (2.054 a 2.692)	< 0.001	2.342 (2.043 a 2.686)	< 0.001
Growth and Development Control	DEE		DEE		DEE	
No	REF	-0.001	REF	-0.001	REF	-0.001
Yes	1.098 (1.062 a 1.136)	< 0.001	<u>1.209 (1.125 a 1.299)</u>	< 0.001	1.194 (1.11 a 1.284)	< 0.001


aPR: adjusted Prevalence Ratio, REF: Category used as a reference for estimating the measure of effect.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.03.24308410; this version posted June 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. Table 4. Inequality in compliance with the two doses of measles vaccination in children between 12 and 59 months of age


	Received First Dose		Received Second Do	se	Received Both Doses	
Variables	ECI (95%CI)	P- value	ECI (95%CI)	P- value	ECI (95%CI)	P- value
Mother's Characteristics						
Age Group						
15 to 17 years old	-0.267 (-0.705 a 0.171)	0.237	0.022 (-0.336 a 0.379)	0.905	0.022 (-0.336 a 0.379)	0.905
18 to 29 years old	0.062 (0.012 a 0.112)	0.015	0.062 (-0.003 a 0.128)	0.061	0.076 (0.009 a 0.143)	0.026
30 to 49 years old	0.045 (0.016 a 0.073)	0.002	0.005 (-0.047 a 0.058)	0.843	0.008 (-0.045 a 0.062)	0.763
Educational Level						
No Education	0.168 (0.044 a 0.292)	0.010	0.31 (0.133 a 0.486)	0.001	0.313 (0.136 a 0.49)	0.001
Elementary	0.048 (-0.019 a 0.115)	0.161	0.03 (-0.064 a 0.124)	0.535	0.044 (-0.051 a 0.139)	0.366
High School	0.049 (0.01 a 0.089)	0.014	0.053 (-0.005 a 0.111)	0.074	0.064 (0.005 a 0.123)	0.033
University	0.009 (-0.029 a 0.048)	0.635	0.019 (-0.046 a 0.085)	0.565	0.029 (-0.038 a 0.096)	0.394
Natural Region			· · · · · ·			
Metropolitan Lima	0.041 (-0.016 a 0.097)	0.158	0.029 (-0.057 a 0.115)	0.508	0.033 (-0.053 a 0.119)	0.448
Rest of the Coast	0.026 (-0.017 a 0.07)	0.236	-0.026 (-0.099 a 0.047)	0.481	0.006 (-0.055 a 0.067)	0.839
Highlands	0.024 (-0.017 a 0.066)	0.252	0.052 (-0.004 a 0.108)	0.070	0.048 (-0.01 a 0.105)	0.106
Jungle	0.136 (0.089 a 0.182)	<0.001	0.114 (0.052 a 0.176)	<0.001	0.133 (0.069 a 0.197)	<0.001
Area of Residence						
Urban	0.049 (0.018 a 0.079)	0.002	0.025 (-0.024 a 0.074)	0.324	0.036 (-0.01 a 0.083)	0.128
Rural	0.04 (0.008 a 0.071)	0.013	0.023 (-0.023 a 0.07)	0.330	0.028 (-0.02 a 0.077)	0.247
Health Insurance	, , , , , , , , , , , , , , , , , , ,		(, , , , , , , , , , , , , , , , , , ,		()	
Yes	0.052 (0.024 a 0.08)	<0.001	0.138 (-0.02 a 0.296)	0.087	0.136 (-0.022 a 0.294)	0.093
No	0.221 (0.128 a 0.315)	<0.001	0.036 (-0.007 a 0.08)	0.102	0.048 (0.005 a 0.091)	0.028
Antenatal Care Visits	, , , , , , , , , , , , , , , , , , ,		(, , , , , , , , , , , , , , , , , , ,			
Less than Six	0.143 (0.055 a 0.23)	0.001	0.003 (-0.114 a 0.121)	0.956	0.015 (-0.102 a 0.132)	0.800
Six or More	0.038 (0.012 a 0.064)	0.004	0.027 (-0.019 a 0.072)	0.251	0.033 (-0.011 a 0.077)	0.141
Received Tetanus Vaccine	, , , , , , , , , , , , , , , , , , ,					
No	0.102 (0.034 a 0.17)	0.003	0.092 (0.003 a 0.181)	0.043	0.099 (0.011 a 0.188)	0.028
Yes	0.047 (0.02 a 0.074)	0.001	0.018 (-0.03 a 0.066)	0.463	0.026 (-0.022 a 0.074)	0.293
Institutional Labor	,		, ,			
No	0.035 (-0.154 a 0.225)	0.716	-0.056 (-0.202 a 0.09)	0.451	-0.032 (-0.177 a 0.113)	0.667
Yes	0.048 (0.021 a 0.074)	<0.001	0.03 (-0.011 a 0.072)	0.155	0.041 (0 a 0.081)	0.051
Children's Characteristics						
Age (months)						
12 to 23	0.029 (-0.042 a 0.1)	0.425	0.005 (-0.066 a 0.076)	0.890	0.02 (-0.051 a 0.091)	0.575
24 to 35	0.052 (0.002 a 0.102)	0.044	0.028 (-0.057 a 0.113)	0.524	0.05 (-0.038 a 0.137)	0.265
36 to 47	0.072 (0.025 a 0.118)	0.003	0.04 (-0.038 a 0.119)	0.317	0.045 (-0.036 a 0.125)	0.275
48 to 59	0.069 (0.032 a 0.107)	<0.001	0.028 (-0.048 a 0.104)	0.471	0.038 (-0.041 a 0.116)	0.347
Growth and Development	,,				,,	
Control						
No	0.133 (0.084 a 0.182)	<0.001	0.145 (0.073 a 0.218)	<0.001	0.142 (0.069 a 0.215)	<0.001
Yes	0.025 (-0.004 a 0.055)	0.091	-0.025 (-0.075 a 0.025)	0.330	-0.012 (-0.063 a 0.039)	0.644


ECI: Erreyger Concentration Index





CI: Concentration Index.





ECI: Erreygers Concentration Index